MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Supernus Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

32.46 -1.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

31.94

Max

32.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

-23M

15M

Verkäufe

-1.5M

174M

KGV

Branchendurchschnitt

24.811

63.778

EPS

0.548

Gewinnspanne

8.801

Angestellte

674

EBITDA

-20M

45M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+18.22% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-272M

1.8B

Vorheriger Eröffnungskurs

33.65

Vorheriger Schlusskurs

32.46

Nachrichtenstimmung

By Acuity

67%

33%

346 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Supernus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Apr. 2024, 18:04 UTC

Wichtige Markttreiber

Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready

Peer-Vergleich

Kursveränderung

Supernus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

18.22% Vorteil

12-Monats-Prognose

Durchschnitt 38.8 USD  18.22%

Hoch 44 USD

Tief 36 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Supernus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

2

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

32.3399 / 32.9Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

346 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.